Julphar resumes sales of products in Bahrain and Kuwait

After an inspection of Julphar facilities, the Gulf Health Council and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin, Ministry of Health, State of Kuwait has lifted the temporary suspension on the export of Julphar products to Bahrain and Kuwait

  
Julphar resumes sales of products in Bahrain and Kuwait

Ras Al Khaimah (UAE) –Gulf Pharmaceutical Industries PSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced that the company’s exports to Bahrain and Kuwait will resume again. The announcement comes after the successful inspection of Julphar’s manufacturing facilities by the Gulf Health Council (GHC) and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin, Ministry of Health, State of Kuwait.

His Highness Sheikh Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said: “We are very pleased to announce that, once again, more than 100 products will be registered and available within Bahrain and Kuwait. We would like to extend our thanks to the authorities for their continued guidance and support during our collaboration to implement further improvements in our manufacturing processes as per the recommendations highlighted in their report. We look forward to being able to serve patients in both countries once again, as well as further bolstering our long-standing relationships and efforts with all relevant Bahraini, Kuwaiti and regional authorities as our products continue to be successfully sold here and in 50 markets around the world.”

Commenting on the lift, Dr. Essam Farouk, Chief Executive Officer at Julphar, said:

In 2019, Julphar began its operational transformation including an internal restructure and a cutting-edge revamp of all quality processes. This included a key focus on the company’s quality assurance, regulatory and development activities steered by over 200 scientists, medical professionals and regulatory experts to ensure Julphar delivers impactful and accessible healthcare solutions that respond to the needs of people and governments across the region and beyond.

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases